Sign In
Buy TMDX
$71.37
+1.68 (+2.41%)
At Close: Jun 04, 2026
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q3 2021 Results - Earnings Call Transcript
09:37pm, Tuesday, 09'th Nov 2021
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q3 2021 Results - Earnings Call Transcript
TransMedics (TMDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
04:06pm, Tuesday, 02'nd Nov 2021
TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
12:30pm, Wednesday, 08'th Sep 2021
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
TransMedics' OCS Heart System Scores FDA Approval
11:11am, Tuesday, 07'th Sep 2021
TransMedics Group Inc (NASDAQ: TMDX) has received FDA premarket approval (PMA) for its OCS Heart system. Related content: Benzinga's Full FDA Calendar.
TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
04:05pm, Thursday, 26'th Aug 2021
ANDOVER, Mass., Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics: Transforming Lives, Potentially Transforming Stock
04:36am, Sunday, 22'nd Aug 2021
TransMedics has seen continued progress in the business, mostly on the research front. The pandemic is still halting revenue growth as more approvals and lifting of restrictions might drive growth fro
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2021 Results - Earnings Call Transcript
10:49am, Sunday, 08'th Aug 2021
TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2021 Results - Earnings Call Transcript
TransMedics (TMDX) Reports Q2 Loss, Tops Revenue Estimates
10:03pm, Thursday, 05'th Aug 2021
TransMedics (TMDX) delivered earnings and revenue surprises of -44.44% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs
06:20pm, Thursday, 29'th Jul 2021
ANDOVER, Mass., July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference
04:05pm, Wednesday, 28'th Jul 2021
ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021
04:05pm, Thursday, 22'nd Jul 2021
ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System
09:00pm, Wednesday, 14'th Jul 2021
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics Group's stock is halted in advance of FDA committee meeting
07:30am, Wednesday, 14'th Jul 2021
Shares of TransMedics Group Inc. were halted on Wednesday in advance of an advisory committee meeting scheduled for the same day by the Food and Drug Administration. The committee is expected to revie
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System
07:05am, Wednesday, 14'th Jul 2021
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
10:35am, Thursday, 10'th Jun 2021
ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
